List view / Grid view
Biomarkers are a naturally occurring molecule, gene, or characteristic by which a particular disease can be identified.
Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and regulatory hurdles of antibody development, how these therapies compare to existing immunotherapies, and the potential for personalised cancer treatment through biomarker development.
The study highlights the possible therapeutic significance of targeting the pathway for treating obesity and metabolic disease.
Orlando Health Orlando Regional Medical Center is the first hospital in the world to use the blood test.
Protein biomarkers in spinal fluid linked to PSP could enable earlier diagnosis and treatment for this neurological disorder.
Researchers identified miR-519a-3p as a biomarker that could enable early diagnosis and treatment of neurodegenerative diseases.
The screening model combines maternal history, ultrasound data and several tests for blood markers to enable personalised treatment.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
In this Q&A, Debiopharm’s Principal Scientist Dr Luke Piggott defines the critical requirement of biomarkers for identifying rare diseases. He illuminates how AI-enhanced approaches are accelerating the drug discovery process, particularly regarding clinical trial enrolment, and the breakthroughs he hopes to see in the future.
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
Epigenetic data assessing the effects of smoking on DNA methylation could serve as biomarkers of exposure effects.
Elevated levels of trimethylamine N-oxide levels were a stronger indicator of CKD risk than the well-known risk factors.
Scientists have examined gene activity in mice models, noting important indicators of liver disease severity which may be used as therapeutic strategies.
Understanding heart changes at the molecular level during early infection with adenovirus could enable identification of those at higher risk of arrhythmia.
Proteins regulating plasminogen-plasmin levels can be used to identify patients at risk of progressing to a severe stage of COVID-19.
Researchers highlight the need for considering biomarkers alongside other health outcomes, as well as the need for omic data standardisation.
